By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Rheonix has closed on a $6 million extension to its Series A financing round, bringing the total raised in the round to $18.6 million.

Tony Eisenhut, the firm's president, told GenomeWeb Daily News today that the funds will be used to continue developing four tests: a warfarin-sensitivity test; a sexually transmitted disease panel; an HIV panel; and a CYP2C19 test for predicting response to the anti-platelet drug Plavix (clopidogrel).

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.